Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced or metastatic cutaneous melanoma AJCC Stage IIIB to IV, not potentially curable with surgery
BRAF or NRAS mutation in tumor tissue
All patients enrolled should provide sufficient fresh or archival tumor sample at baseline to enable confirmation of BRAF or NRAS mutations and the additional analyses described in the protocol
Evidence of measurable tumor disease as per RECIST
WHO performance status of 0-2
Adequate organ function and laboratory parameters
You may not be if
History or evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or any eye condition that would be considered a risk factor for CSR or RVO
Patients with unstable CNS metastasis
Prior treatment with a MEK- inhibitor
Impaired cardiovascular function
HIV, active Hepatitis B, and/or active Hepatitis C infection
Pregnant or nursing (lactating) women
Women of child-bearing potential UNLESS they comply with protocol contraceptive requirements
Clareo Health | A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
